This story is part of the KXAN Data Hub, where numbers help tell the whole story. We’ve created several data-driven stories and databases on topics including weather and climate, politics, education, ...

With the recent launches of Novo Nordisk’s Wegovy pill and Eli Lilly’s Foundayo, the obesity market has started to shift toward oral GLP-1 drugs. While Novo leverages its first-mover advantage with ...